For decades, the standard of care for depression, anxiety, and PTSD has left one-third of patients without adequate symptom relief. Psychedelic-assisted therapies could fill some of that unmet medical need, and this potential is gaining momentum with every new clinical trial readout and acquisition announcement in the field.
OPEN Health analyzed more than 150,000 social media posts on psychedelic treatments for psychiatric indications across nine distinct narrative themes from March 2025 through April 2026. The intent of this analysis was to contextualize the big news stories within the conversations happening in the communities of patients and physicians most directly impacted by the changing landscape.
We have reserved a copy of this whitepaper for you.
We are excited to share our latest thinking with you.
Please fill out the form to download the whitepaper.
At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact.
By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.
